Home > Journals > Panminerva Medica > Past Issues > Panminerva Medica 1999 March;41(1) > Panminerva Medica 1999 March;41(1):15-7





A Journal on Internal Medicine

Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,6




Panminerva Medica 1999 March;41(1):15-7

language: English

Clinical and haemostatic effects of intravenous prostaglandin E1 therapy in patients with peripheral arterial occlusive disease

Trifiletti A., Scamardi R., Pizzoleo M. A., Sottilotta G., Soraci S., Attinà A., Bagnato L., Barbera N.

From the Department of Internal Medicine University of Messina, Italy


Background. In this study the action of an antiaggregatory prostaglandin, PGE1, was studied in a group of patients with peripheral arterial occlusive disease (PAOD).
Methods. In 16 patients with PAOD Fontaine stage IIb and III the clinical and haemostatic effects of the endovenous administration of 60 μg/die of alprostadil-PGE1 for four weeks, were evaluated. Before and after pharmacological treatment, were evaluated the clinical symptoms (claudicatio intermittens and rest pain) and the following haemostatic parameters: plasma thrombomodulin (TM), beta-thromboglobulin (β-TG), D-dimer (DD), tissue-type plasminogen activator (t-PA) and plasminogen activator-inhibitor (PAI-1).
Results. No significant difference in plasma TM, t-PA and PAI-1 levels was observed after the treatment. On the other hand the patients showed plasma levels of β-TG and DD significantly decreased at the end of the treatment. From the clinical point of view both claudicatio intermittens and rest pain satisfactorily improved in all patients.
Conclusions. This data confirmed the therapeutic efficacy of PGE1 in the treatment of PAOD patients.

top of page

Publication History

Cite this article as

Corresponding author e-mail